Research Paper Volume 16, Issue 10 pp 9047—9071
Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma
Figure 7. PRKDC knockdown represses the invasiveness of LIHC cells. (A) PRKDC expression in LIHC tissues from protein atlas. (B) PRKDC expression in LIHC cell lines from protein atlas. (C) Expression of PRKDC mRNA in Huh-7 or Hep-3B using qPCR. (D, E) Protein level of PRKDC in Huh-7 or Hep-3B using WB. (F) Cell viability in PRKDC knockdown and negative control groups. (G) Clone formation assays between PRKDC knockdown and negative control groups. (H) Would healing assays between PRKDC knockdown and negative control groups. (I) Relative migration of Huh-7 or Hep-3B cells between PRKDC knockdown and negative control groups.